Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. In the past five years, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a ...

In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.